Oumar AA, Maiga M, Dembele JP, Djibril N, Sangho F, Konate I, Kone Y , Guida L, Tulkens PM, Dao S
Adverse neurological events due to antiretroviral therapy in Mali
International Journal of Research in Pharmacology & Pharmacotherapeutics (2015) 4:455-459


Adverse neurological events during antiretroviral treatment (ART) are frequent and various1-3. Their diagnosis
is difficult in developing countries where human resources and infrastructures are most of the time lacking.

To identify the frequency of neurological side effects in patients under ART in Mali

We performed a prospective cohort study on patients developing neurological symptoms in a period of 12
months at the Department of Infectious Diseases of the Teaching Hospital “Point G” of Bamako, Mali.
Neurological diagnostic was established with the guidance of a neurologist. WHO’s sides effects table has been
used to characterize and classify the side effects4. Analysis of data was performed with SPSS Software, version

A total of 420 HIV seropositive patients under ART have been followed. Of those, 37 cases were found with
adverse neurological events (8.08%). The sex ratio M/F was 1.06 and. the mean age was 41.2 years. Of the side
effects, polyneuritis alone represented 83.8% of the cases, and polyneuritis associated to vertigo, headache and
depression represented the remaining 16.2 %. We didn’t notice any these neurological symptoms at the initiation
of the ART. The majority of the patients was infected by HIV-1 (91.9 %). Most of the patients, 89.2% were
treated with a fixed dose combination of Triomune® (D4T+3TC +Nevirapine). Five cases were at 3rd stage of
WHO classification (13.5%), which justified stopping the treatment with d4T.

The use of Triomune® led to neurological adverse events in Mali. Any further new antiretroviral regimens must
include a pharmacovigilance to detect eventual neurological side effects.
Keywords: Adverse neurological events, Pharmacovigilance, Antiretroviral therapy, Mali